Kodiak Sciences (KOD) director awarded stock options for 17,731 shares at $38.96

Rhea-AI Filing Summary

Kodiak Sciences director Charles A. Bancroft received a new stock option grant, giving him the right to buy 17,731 shares of common stock at an exercise price of $38.96 per share. These options were granted at no cost to him on June 30, 2026.

The entire option grant vests in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, as long as Bancroft continues to serve on the company’s board of directors through that vesting date. After this grant, he holds options for 17,731 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bancroft Charles A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,731	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 17,731 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 17,731 shares Exercise price: $38.96 per share Shares underlying options: 17,731 shares +3 more

6 metrics

Option shares granted 17,731 shares Stock Option (Right to Buy) grant on June 30, 2026

Exercise price $38.96 per share Strike price for the 17,731 option shares

Shares underlying options 17,731 shares Common stock underlying the new option award

Post-grant option holdings 17,731 options Total derivative shares following the reported transaction

Option expiration date June 29, 2036 Final date to exercise the granted options

Cliff vesting date June 30, 2027 Latest vesting trigger if earlier annual meeting date does not apply

Key Terms

Stock Option (Right to Buy), exercise price, vest, board of directors

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "38.9600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

board of directors financial

"provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 05:52 PM Accepted by SEC EDGAR 07/02/2026 - 05:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bancroft Charles A

(Last) (First) (Middle)

1250 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kodiak Sciences Inc. [ KOD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$38.96	06/30/2026		A		17,731		(1)	06/29/2036	Common Stock	17,731	$0	17,731	D

Explanation of Responses:

1. One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.

	/s/ David Peinsipp, Attorney-in-Fact for Charles Bancroft	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kodiak Sciences (KOD) director Charles Bancroft report on this Form 4?

Charles A. Bancroft reported receiving a stock option grant for 17,731 shares of Kodiak Sciences common stock. The options are a compensation award and not an open-market purchase, reflecting a new right to buy shares rather than an immediate cash transaction or sale.

How many Kodiak Sciences (KOD) shares are covered by Bancroft’s new stock options?

The new option grant covers 17,731 shares of Kodiak Sciences common stock. These options give Bancroft the right to acquire that number of shares in the future, subject to vesting conditions and payment of the stated exercise price if exercised.

What is the exercise price of Charles Bancroft’s Kodiak Sciences stock options?

The options have an exercise price of $38.96 per share. This means Bancroft can purchase Kodiak Sciences common stock at $38.96 for each share covered by the option if he exercises after the options have vested and before they expire.

When do Charles Bancroft’s Kodiak Sciences options vest?

One hundred percent of the option shares vest on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual meeting after the grant date. Vesting requires that Bancroft continue serving on the board through the applicable vesting date.

When do the newly granted Kodiak Sciences stock options expire?

The options expire on June 29, 2036. After that expiration date, Bancroft can no longer exercise the options to buy Kodiak Sciences shares, even if they have vested and were previously exercisable during the option term.

Is this Kodiak Sciences (KOD) Form 4 a stock purchase or a compensation award?

This filing reflects a compensation-related award, not an open-market purchase. Bancroft received stock options at no cost, giving him the right to buy shares later. The transaction is classified as a grant or award acquisition under code A, a routine director compensation mechanism.